The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.

Read more: http://www.clinicaltrials.gov/ct2/show/NCT02024646?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30